FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments

Gilead Science's remdesivir, an antiviral medicine being tested for treatment of COVID-19, would get a seven-year monopoly if approved by the Food and Drug Administration.

(Image credit: Andrew Harnik/AP)

from Health : NPR https://ift.tt/2wA8h8e